Fallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Abnormal growth of malignant cells in one or both fallopian tubes in women can cause fallopian tube cancer. The increased incidence of fallopian tube cancer cases, increased research and development of treatment, the necessity of approvals, untapped opportunities, and upcoming technological advancements drive market growth.
New York, USA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Fallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Abnormal growth of malignant cells in one or both fallopian tubes in women can cause fallopian tube cancer. The increased incidence of fallopian tube cancer cases, increased research and development of treatment, the necessity of approvals, untapped opportunities, and upcoming technological advancements drive market growth.
DelveInsight’s 'Fallopian Tube Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline fallopian tube cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the fallopian tube cancer pipeline domain.
Key Takeaways from the Fallopian Tube Cancer Pipeline Report
DelveInsight’s fallopian tube cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for fallopian tube cancer treatment.
Key fallopian tube cancer companies such as ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others are evaluating new drugs for fallopian tube cancer to improve the treatment landscape.
Promising fallopian tube cancer pipeline therapies in various stages of development include Mirvetuximab Soravtansine, Trabectedin, Navicixizumab, Pembrolizumab, Nemvaleukin, DCVAC/OvCa, Fluzoparib, AL3818, Oregovomab, Enzalutamide, PF-06873600, PankoMab-GEX, VTX-2337, Guadecitabine, Gimatecan, tisotumab vedotin, SG001, ZEN003694, AVOVA-1, Abemaciclib, XmAb20717, Entinostat, DPX-Survivac, GEN-1, ATX-101, GRN-300, TG4050, CART-TnMUC1, Olvimulogene nanivacirepvec, ONC-392, Oregovomab, ZN-c3, ART0380, IMGN151, SL-172154, TG4050, STRO-002, XMT-1660, RP12146, ATRC-101, and others.
Mirvetuximab soravtansine being developed by ImmunoGen is a first-in-class antibody-drug conjugate which consists of a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, in order to kill the targeted cancer cells. SORAYA is a global, single-arm, phase III study evaluating mirvetuximab soravtansine in adults with folate receptor alpha–high, platinum-resistant, high-grade, serous epithelial ovarian, primary peritoneal, or fallopian tube cancer. As per the results, Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers.
SL-172154 is a bi-functional fusion protein that targets CD47 on malignant cells and CD40 on immune cells (antigen presenting cells). In August 2022, Shattuck Labs initiated a SL03-OHD-105 an open-label, multicenter, phase Ib trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer.
ATX-101, the lead compound of APIM’s development program, is being evaluated in combination with platinum-based chemotherapy in patients suffering from recurrent, platinum sensitive ovarian, fallopian tube and primary peritoneal cancer in Phase I/II stage of developement. In May 2021, US FDA accepted its Investigational New Drug application (IND) for a Phase I/II clinical trial.
IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). In October 2022, ImmunoGen initiated a Phase I, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.
Request a sample and discover the recent advances in fallopian tube cancer treatment drugs @Fallopian Tube Cancer Pipeline Report
The fallopian tube cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage fallopian tube cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the fallopian tube cancer clinical trial landscape.
Fallopian Tube Cancer Overview
Fallopian tube cancer begins in the fallopian tubes, which connect a woman's ovaries to her uterus. Fallopian tube cancer is extremely rare. Only about 1% of all reproductive cancers in women begin in the fallopian tubes. The fallopian tube cancer causes and risk factors are unknown. In some cases, a woman may have a history of chronic infection and inflammation of the fallopian tubes (due to untreated sexually transmitted diseases, for example).
The most common fallopian tube cancer symptoms are abnormal vaginal bleeding, vaginal discharge, and/or abdominal pain. It is difficult to see anything abnormal growing inside a fallopian tube. This makes fallopian tube cancer diagnosis difficult.
Fallopian tube cancer treatment will consider the patient’s disease stage, medical history, current health, and personal preferences, among other things. Fallopian tube cancer treatment aims to eradicate cancer with minimal side effects completely.
Find out more about fallopian tube cancer treatment drugs @Drugs for Fallopian Tube Cancer Treatment
A snapshot of the Fallopian Tube Cancer Pipeline Drugs mentioned in the report:
Drugs | Company | Phase | MoA | RoA |
Mirvetuximab Soravtansine | ImmunoGen | Phase III | Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors | Intravenous |
Pembrolizumab | Merck & Co. | Phase III | Programmed cell death-1 receptor antagonists | Intravenous |
Nemvaleukin | Alkermes plc | Phase III | Interleukin-2 receptor agonists | Intravenous |
Oregovomab | CanariaBio Inc. | Phase III | Antibody-dependent cell cytotoxicity; Immunostimulants | Intravenous |
ZEN003694 | Zenith Epigenetics | Phase II | Bromodomain and extraterminal domain protein inhibitors | Oral |
AVOVA-1 | Aivita Biomedical | Phase II | Immunostimulants | Subcutaneous |
PF-06873600 | Pfizer | Phase II | Cyclin-dependent kinase inhibitors | Oral |
ATX-101 | Apim Therapeutics | Phase I/II | Protein interaction domain and motif inhibitors | Intravenous |
REGN5668 | Regeneron Pharmaceuticals | Phase I/II | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Intravenous |
IMGN151 | ImmunoGen, Inc. | Phase I | Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors | Intravenous |
SL-172154 | Shattuck Labs | Phase I | CD40 antigen stimulants; CD47 antigen inhibitors; Cytokine stimulants; Immunologic cytotoxicity; Phagocyte stimulants; T lymphocyte stimulants | Intravenous |
TG4050 | Transgene | Phase I | Immunostimulants; T lymphocyte stimulants | Subcutaneous |
Learn more about the emerging fallopian tube cancer pipeline therapies @Fallopian Tube Cancer Clinical Trials
Fallopian Tube Cancer Therapeutics Assessment
The fallopian tube cancer pipeline report proffers an integral view of fallopian tube cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Fallopian Tube Cancer Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule
Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Mitosis inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, Interleukin-2 receptor agonists, Fibroblast growth factor receptor antagonists, Platelet-derived growth factor beta receptor antagonists, Proto oncogene protein c-kit inhibitors, Bromodomain and extraterminal domain protein inhibitors,
Key Fallopian Tube Cancer Companies: ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others
Key Fallopian Tube Cancer Pipeline Therapies: Mirvetuximab Soravtansine, Trabectedin, Navicixizumab, Pembrolizumab, Nemvaleukin, DCVAC/OvCa, Fluzoparib, AL3818, Oregovomab, Enzalutamide, PF-06873600, PankoMab-GEX, VTX-2337, Guadecitabine, Gimatecan, tisotumab vedotin, SG001, ZEN003694, AVOVA-1, Abemaciclib, XmAb20717, Entinostat, DPX-Survivac, GEN-1, ATX-101, GRN-300, TG4050, CART-TnMUC1, Olvimulogene nanivacirepvec, ONC-392, Oregovomab, ZN-c3, ART0380, IMGN151, SL-172154, TG4050, STRO-002, XMT-1660, RP12146, ATRC-101, and others.
Dive deep into rich insights for new drugs for fallopian tube cancer treatment, visit @Fallopian Tube Cancer Medications
Table of Contents
1. | Fallopian Tube Cancer Pipeline Report Introduction |
2. | Fallopian Tube Cancer Pipeline Report Executive Summary |
3. | Fallopian Tube Cancer Pipeline: Overview |
4. | Analytical Perspective In-depth Commercial Assessment |
5. | Fallopian Tube Cancer Clinical Trial Therapeutics |
6. | Fallopian Tube Cancer Pipeline: Late Stage Products (Pre-registration) |
7. | Fallopian Tube Cancer Pipeline: Late Stage Products (Phase III) |
7.1 | Mirvetuximab Soravtansine: ImmunoGen |
8. | Fallopian Tube Cancer Pipeline: Mid Stage Products (Phase II) |
8.1 | ZEN003694: Zenith Epigenetics |
9. | Fallopian Tube Cancer Pipeline: Early Stage Products (Phase I) |
9.1 | SL-172154: Shattuck Labs |
10. | Fallopian Tube Cancer Pipeline Therapeutics Assessment |
11. | Inactive Products in the Fallopian Tube Cancer Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Key Companies |
14. | Key Products in the Fallopian Tube Cancer Pipeline |
15. | Unmet Needs |
16. | Market Drivers and Barriers |
17. | Future Perspectives and Conclusion |
18. | Analyst Views |
19. | Appendix |
For further information on the fallopian tube cancer pipeline therapeutics, reach out @Fallopian Tube Cancer Treatment Drugs
Related Reports
Fallopian Tube Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key fallopian tube cancer companies including Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, among others.
Fallopian Tube Cancer Epidemiology Forecast
Fallopian Tube Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted fallopian tube cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Ovarian Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Genentech, Genmab, AstraZeneca, BioNumerik Pharmaceuticals, On Target Laboratories, among others.
Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ovarian cancer companies, including Genentech, Genmab, AstraZeneca, BioNumerik Pharmaceuticals, On Target Laboratories, among others.
Advanced Ovarian Cancer Pipeline
Advanced Ovarian Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced ovarian cancer companies, including ImmunoGen, OncoQuest, Lee's Pharmaceutical, Allarity Therapeutics, among others.
Polycystic Ovarian Syndrome Pipeline
Polycystic Ovarian Syndrome Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycystic ovarian syndrome companies, including Dexa Medica Group, AbbVie, Kindex Pharmaceuticals, Spruce Biosciences, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
